Neuphoria adopts poison pill after investor accumulates >20%; launches strategic review

Neuphoria Therapeutics Inc.

Rights plan triggered if any entity acquires 15%+ beneficial ownership without board approval.
Adopted after an individual investor disclosed >20% ownership as of Oct 23, 2025.
Rights expire Oct 27, 2026; no dead-hand/slow-hand provisions.
Board also evaluating strategic alternatives to maximize stockholder value.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Neuphoria Therapeutics Inc. issued common stock.

Security: common stock

Exact text from the filing

the Board declared a dividend of one preferred share purchase right for each outstanding share of the Company’s common stock as of the close of business on October 27, 2025, the record date

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Neuphoria Therapeutics Inc.: Adoption of Certificate of Designations establishing Preferred Shares and their rights (effective 2025-10-27).

Change: charter amendment
Effective: 2025-10-27

Exact text from the filing

Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the adoption of the Rights Agreement referenced in Item 1.01 above, the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October 27, 2025.

View on SEC.gov

226 equity issuances filed in the last 30 days. Browse all equity issuances →

Neuphoria Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-102607

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.